U.S. Department of Health and Human Services
Clinical Trials Search Results
Search results 1 - 10 of 24 for FDA-Approved Opportunistic Infection and Coinfection Drugs, Daclatasvir
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
Condition: Hepatitis C Virus Infection, Response to Therapy of; Human Immunodeficiency Virus
NCT ID: NCT03369327- Red stop iconCompleted
- Email this trial
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
Condition: HIV-HCV
NCT ID: NCT02124044- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders
Condition: HCV-HIV Co-Infection
NCT ID: NCT01725542- Red stop iconCompleted
- Email this trial
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
Condition: Hepatitis C
NCT ID: NCT02556086- Red stop iconWithdrawn
- Email this trial
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Condition: Hepatitis C
NCT ID: NCT02032888- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
Condition: Hepatitis C, Genotype 1
NCT ID: NCT01471574- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
Condition: Chronic Hepatitis C Infection
NCT ID: NCT01866930- Red stop iconCompleted
- Email this trial
Hepatitis C Treatment Study in Myanmar
Condition: Hepatitis C
NCT ID: NCT03158857- Green tick iconNot yet recruiting
- Email this trial
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
Condition: Hepatitis C; HIV
NCT ID: NCT02565888- Red stop iconCompleted
- Email this trial
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
Condition: HIV-1-infection; Hepatic Impairment
NCT ID: NCT03706898- Green tick iconRecruiting
- Email this trial
Email Updates
